Every material Form 8-K DarioHealth Corp. has filed with the SEC since July 22, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
DarioHealth Corp. said its board appointed John R. Palumbo as Chairman effective immediately, on November 3, 2026, following a recommendation from the Nominating Committee. He replaces Yoav Shaked, who remains on the board as a member. The filing does not state any financial results or reasons for the change.
Appointment made November 3, 2026, on the recommendation of the Nominating Committee
John R. Palumbo became Chairman of the Board effective immediately
Yoav Shaked steps down as Chairman but will continue to serve as a board member
DarioHealth Corp. disclosed that director Lawrence Leisure has retired from its Board of Directors, effective September 2, 2026, citing personal reasons. The company said the decision was not the result of any disagreement over its operations, policies or practices.
Lawrence Leisure notified the Board on September 2, 2026 of his decision to retire, effective the same day.
The filing cites personal reasons and states no disagreement with the company on operations, policies or practices.
The 8-K was signed September 4, 2026 by CFO, Treasurer and Secretary Chen Franco-Yehuda.
DarioHealth said President and Chief Commercial Officer Steven Nelson will stop serving in that role on September 1, 2026, and his employment ends September 30, 2026, under a separation agreement signed August 20, 2026. Nelson will then provide consulting services through December 31, 2027, for which the company plans to grant him 30,000 restricted shares, subject to Compensation Committee approval.
Nelson ceases as President and Chief Commercial Officer effective September 1, 2026; employment ends September 30, 2026.
Company will reimburse up to three months of COBRA health coverage at $2,600 per month after the separation date.
Consulting agreement effective October 1, 2026, runs through December 31, 2027, with a grant of 30,000 restricted shares, subject to Compensation Committee approval.
On July 22, 2026, DarioHealth agreed to sell 2,437,060 common shares and pre-funded warrants for 1,017,499 shares to institutional investors in a registered direct offering priced at-the-market under Nasdaq rules, for gross proceeds of about $23.5 million before fees. The sale adds new shares outstanding, and the company has agreed not to issue more shares for 30 days after closing, which is expected on or about July 23, 2026, apart from its existing at-the-market facility.
Shares priced at $6.80 each; pre-funded warrants priced at $6.7999 each, covering 1,017,499 shares
Gross proceeds of about $23.5 million; placement agent cash fee of 6.0%, with a 1.0% fee on certain investor proceeds, plus expenses up to $60,000
Board member Dennis Matheis agreed to buy 14,430 shares at $6.93 per share
Company may not issue further shares for 30 days after closing, expected on or about July 23, 2026, except under its existing at-the-market facility and Form S-8 plans
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every DarioHealth Corp. filing is on SEC EDGAR ↗. 8-K briefs of other companies →